



## COVID-19 and Vaccination Strategies in Global Health

Guest Editor:

**Dr. Davide Barbieri**

Department of Neuroscience and  
Rehabilitation, University of  
Ferrara, Ferrara, Italy

Deadline for manuscript  
submissions:

**closed (31 March 2024)**

### Message from the Guest Editor

We have faced challenging times since the beginning of the COVID-19 pandemic. It has affected us all in an unprecedented way, pushing medical authorities, pharmaceutical companies, scientists, patients, and their relatives to find and test solutions which could limit the spread of the Sars-Cov-2 virus or its consequences on our health and on our lives.

As we all know, vaccines have played a major role, both in the scientific debate and in the attempt to contain the pandemic. The year 2022, the third year since the start of the pandemic, has provided an opportunity to update what we know, revise what we thought, and envisage what can be done further to manage pandemics such COVID-19 and eventually prevent future ones.

I therefore invite you all to contribute to this Special Issue of Vaccines on ‘COVID-19 and Vaccination Strategies in Global Health’ with original research articles, reports, and reviews. The scope of this Special Issue is purposefully wide, in order to tackle different points of view: immunology, infectiology, epidemiology, public health, primary care, and medical statistics.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Ralph A. Tripp

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia,  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

**Journal Rank:** JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

## Contact Us

---

*Vaccines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)